According to a recent LinkedIn post from Resolution Therapeutics, CEO Amir Hefni discussed progress on the company’s EMERALD clinical program in an interview with BiotechTV. The post indicates that the interim analysis cohort has been fully recruited and that an interim data readout is targeted for the end of Q3 2026, with active recruitment across 15 trial sites split between the U.K. and Spain.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Resolution Therapeutics is maintaining a focused strategy around regenerative macrophage therapies, emphasizing a single-mission approach in this niche of regenerative medicine. For investors, the planned interim analysis timeline and multi-country site footprint may signal advancing clinical execution and potential future value inflection, while also underscoring clinical, regulatory, and data-readout risks typical of early-stage biotech programs.